PRNP-Targeting RNAi Agents for Prion Protein Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases associated with prion protein (PrP) are inadequate in effectively reducing the amount or activity of PRNP RNA and prion protein, leading to progressive and fatal symptoms such as dementia, ataxia, and neuronal loss.
Innovation Solution
Development of RNAi agents, particularly oligomeric duplexes and antisense agents, that target and reduce PRNP RNA expression, thereby decreasing prion protein levels and ameliorating symptoms of neurodegenerative diseases like Creutzfeldt-Jakob disease and Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments are used for neurodegenerative diseases associated with prion protein, then current therapeutic options are available, but the amount and activity of PRNP RNA and prion protein cannot be effectively reduced
Solution Approach 1:
The patent extracts and targets the specific PRNP RNA sequence using RNAi agents (siRNA, miRNA, piRNA) to selectively reduce prion protein expression. The RNAi agents are designed to bind to complementary sequences in PRNP RNA, extracting the harmful genetic information and preventing protein synthesis without affecting other cellular functions.
Solution Approach 2:
The patent modifies the PRNP RNA parameter by introducing RNAi agents that change the expression level of prion protein from normal to reduced. The RNAi agents alter the transcriptional or post-transcriptional parameters of PRNP RNA, leading to decreased prion protein production and subsequent amelioration of neurodegenerative symptoms.
2Quantity of substance
If RNAi agents are developed to target PRNP RNA, then prion protein levels can be reduced, but the complexity of the treatment system increases
Solution Approach 1:
The patent develops RNAi agents that can be universally applied to treat multiple neurodegenerative diseases associated with prion protein (Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, kuru, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontal temporal dementia, Pick's disease, progressive supranuclear palsy, corticobasal neurodegeneration, and chronic traumatic encephalopathy). A single RNAi agent design can reduce prion protein across different disease states, providing multi-functional therapeutic coverage.
3Duration of action of moving object
If current treatments are used, then some therapeutic options exist, but disease progression continues unchecked
Solution Approach 1:
The patent applies preliminary action by introducing RNAi agents that preemptively reduce PRNP RNA and prion protein levels before significant neuronal damage occurs. The RNAi agents are administered to lower prion protein expression early in the disease course, preventing the formation of abnormal protein aggregates and spongiform changes that lead to neuronal loss and symptom progression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively lower PRNP RNA and prion protein levels, slowing disease progression and reducing symptoms like dementia, ataxia, and neuronal loss, providing a therapeutic benefit for neurodegenerative disorders.
Implementation Method 1
RNAi agents, methods, and pharmaceutical compositions for reducing the amount or activity of PRNP RNA in a cell or a subject
Data Source
AI summary
Provided are RNAi agents, pharmaceutical compositions, and methods for reducing the amount or activity of PRNP RNA in a cell or a subject, and in certain instances reducing the amount of prion protein in a cell or a subject. Such RNAi agents, pharmaceutical compositions, and methods are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such neurodegenerative diseases include prion diseases, such as Creutzfeldt-Jakob disease (CJD) (e.g., variant Creutzfeldt-Jakob Disease (vCJD), classic Creutzfeldt-Jakob Disease (cCJD), familial Creutzfeldt-Jakob Disease (fCJD), or sporadic Creutzfeldt-Jakob Disease (sCJD)), Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, or kuru; synucleinopathies such as Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies; or tauopathies such as frontal temporal dementia associated with a Tau mutation, Pick's disease, progressive supranuclear palsy, corticobasal neurodegeneration, or chronic traumatic encephalopathy (CTE).